Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.43 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1606366 | 0.88 | CYP11B2 (0.63) | CYP11B2TBXAS1ESR1MAPK1CYP19A1 | |
| SCHEMBL1605560 | 0.88 | CYP11B2 (0.52) | CYP11B2TBXAS1ARCYP11B1MAPK1 | |
| SCHEMBL1606008 | 0.87 | CYP11B2 (0.52) | CYP11B2TBXAS1ARCYP11B1MAOA | |
| SCHEMBL1604919 | 0.86 | CYP11B2 (0.49) | CYP11B2TBXAS1ARCYP11B1SLC2A1 | |
| SCHEMBL7940338 | 0.83 | CYP11B2 (0.49) | CYP11B2TBXAS1ARESR1CYP11B1 | |
| SCHEMBL1606044 | 0.83 | CYP11B2 (0.49) | CYP11B2TBXAS1ARCYP11B1MAPK1 | |
| SCHEMBL1606173 | 0.83 | AR (0.46) | CYP11B2TBXAS1ARCYP11B1MAPK1 | |
| SCHEMBL11015008 | 0.82 | TBXAS1 (0.62) | CYP11B2TBXAS1ESR1HDAC6 | |
| SCHEMBL1605498 | 0.82 | TBXAS1 (0.54) | CYP11B2TBXAS1ESR1PTGDR2HDAC6 | |
| SCHEMBL30385577 | 0.82 | TBXAS1 (0.54) | CYP11B2TBXAS1ESR1PTGDR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104193725-A | ORGANIC COMPOUNDS | NOVARTIS AG | 2014-12-10 | — | — | CN | claimed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | claimed |
| CN-104193725-B | Organic compound | 诺华股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| CN-104193725-A | ORGANIC COMPOUNDS | NOVARTIS AG | 2014-12-10 | — | — | CN | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| EP-0080154-B1 | N-SUBSTITUTED 2-PYRIDYL INDOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR THERAPEUTICAL USE | CIBA-GEIGY AG (CH) | 1985-08-28 | — | — | EP | disclosed |
| US-4478842-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-10-23 | — | — | US | disclosed |
| US-4460777-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| EP-0080154-A2 | N-substituted 2-pyridyl indoles, process for their preparation, pharmaceutical compositions containing them, and their therapeutical use | CIBA-GEIGY AG (CH) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 13/4885TBXAS1 1987/4885AR 1445/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 12/4885TBXAS1 1766/4885AR 862/4885 |
| US-20140288126-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 12/4885TBXAS1 1766/4885AR 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.